Comprehensive Cardiovascular Pharmacotherapy: Chronic Disease, Acute Coronary Syndromes, and Critical Cardiac Care
Heart Failure: Chronic Management and Acute Decompensation
Heart failure is a complex clinical syndrome resulting from any structural or functional cardiac disorder that impairs ventricular filling or the ejection of blood. In the United States, heart failure affects approximately individuals, and its prevalence rises substantially with advancing age. Heart failure with reduced ejection fraction () is clinically defined by symptoms of heart failure and a left ventricular ejection fraction () of or less, characterized pathologically by ventricular dilation and adverse remodeling. Approximately two-thirds of cases are secondary to chronic coronary disease () following myocardial infarction, while one-third stem from nonischemic cardiomyopathies including chronic uncontrolled hypertension, thyroid disorders, severe obesity, stress cardiomyopathy (Takotsubo), viral or autoimmune myocarditis, tachycardia-mediated cardiomyopathy, peripartum cardiomyopathy, cardiotoxic exposures such as alcohol and cocaine, and chemotherapeutic agents including anthracyclines, high-dose cyclophosphamide, fluorouracil, trastuzumab (with or without pertuzumab/hyaluronidase), and mitoxantrone.
Heart failure with preserved ejection fraction () is defined by an of or greater, representing approximately of all heart failure presentations. The fundamental pathophysiology in involves impaired ventricular relaxation and decreased compliance leading to elevated diastolic filling pressures despite normal wall motion and preserved pump function. Hypertension is the principal etiologic contributor, documented in to of affected patients. Additional clinical classifications include heart failure with mildly reduced ejection fraction (), defined as an of to alongside evidence of increased left ventricular filling pressures, and heart failure with improved ejection fraction (), defined as a baseline of or less that exhibits a subsequent follow-up measurement of greater than with an absolute improvement of at least .
The American College of Cardiology/American Heart Association () staging system categorizes heart failure across four developmental phases, which correspond to the New York Heart Association () functional classification based on subjective symptomatic limitation. Stage A represents patients at high risk for heart failure due to uncontrolled predisposing conditions (such as hypertension, metabolic syndrome, or diabetes) but without structural heart disease, abnormal stretch/injury cardiac biomarkers, or symptoms (no class). Stage B (Pre-heart failure) comprises patients with structural heart disease (such as left ventricular hypertrophy or chamber enlargement), elevated filling pressures, or elevated brain natriuretic peptide () or persistently elevated cardiac troponin in the absence of signs or symptoms ( Class I: asymptomatic without limitation in physical activity). Stage C (Symptomatic heart failure) denotes patients with structural cardiac abnormalities and past or current clinical symptoms ( Class I through IV). Class II reflects slight physical limitation where normal exertion precipitates dyspnea or fatigue, Class III reflects marked limitation where less-than-ordinary exertion produces symptoms but the patient remains comfortable at rest, and Class IV denotes an inability to carry out any physical activity without discomfort or the presence of symptoms at rest. Stage D represents advanced heart failure with refractory symptoms interfering with daily life and recurrent hospitalizations despite maximal guideline-directed medical therapy ().

Guideline-directed medical therapy for chronic prioritizes four foundational drug classes to reduce cardiovascular mortality and heart failure hospitalizations: an angiotensin receptor-neprilysin inhibitor (), an evidence-based -blocker, a mineralocorticoid receptor antagonist (), and a sodium-glucose cotransporter 2 () inhibitor. Initiation does not require sequential completion of individual drug titrations; rather, simultaneous or rapid sequential initiation guided by renal function, serum potassium, heart rate, and blood pressure is recommended, with dose titrations occurring as frequently as every to .
Angiotensin receptor-neprilysin inhibitors, specifically sacubitril/valsartan, carry a Class I recommendation over angiotensin-converting enzyme () inhibitors or angiotensin receptor blockers () for patients with chronic symptomatic ( Class II to III) based on the PARADIGM-HF trial, which demonstrated a relative risk reduction in the primary composite endpoint of cardiovascular death or heart failure hospitalization, a reduction in all-cause mortality, and a reduction in heart failure hospitalizations compared with enalapril. Sacubitril is a prodrug that inhibits neprilysin, thereby preventing the degradation of natriuretic peptides, bradykinin, and adrenomedullin, while valsartan selectively blocks the angiotensin II type 1 () receptor. Because neprilysin degrades , circulating concentrations increase during therapy, whereas N-terminal pro-B-type natriuretic peptide () is not a neprilysin substrate and reflects true hemodynamic unloading. When transitioning from an inhibitor to sacubitril/valsartan, a strict washout period is mandatory to minimize the risk of severe angioedema caused by overlapping inhibition of bradykinin degradation. For patients previously taking low-dose inhibitors (e.g., enalapril , lisinopril , ramipril ) or low-dose (valsartan , losartan ), or those with an estimated glomerular filtration rate () of less than , the starting dose is sacubitril / valsartan orally twice daily. For patients switching from standard or high doses of an inhibitor or , the initial dose is sacubitril / valsartan twice daily. Doses should be doubled every to toward the target maintenance dose of sacubitril / valsartan orally twice daily.
When an is not feasible due to cost, intolerance, or history of angioedema, inhibitors represent a Class I alternative, supported by landmark trials including CONSENSUS, SOLVD, SAVE, AIRE, and TRACE, which documented a to relative risk reduction in mortality and a reduction in hospitalizations. The ATLAS trial established that higher target doses of lisinopril ( to vs. to ) resulted in a significant lower risk of death or hospitalization and fewer hospitalizations for heart failure, underscoring the clinical imperative to titrate to target doses: captopril three times daily (starting at three times daily), enalapril twice daily (starting at twice daily), lisinopril daily (starting at to daily), perindopril daily (starting at daily), ramipril daily (starting at to daily), and trandolapril daily (starting at daily). In patients intolerant of inhibitors due to intractable cough ( incidence) or angioedema ( incidence; cross-reactivity with is approximately ), are indicated (Class I): candesartan titrated from to daily to a target of daily (CHARM-Alternative), losartan titrated from to daily to a target of daily (HEAAL), or valsartan titrated from to twice daily to a target of twice daily (Val-HeFT, VALIANT). Renal function and potassium must be evaluated within to of initiation or dose escalation; an increase in serum creatinine of up to above baseline is considered an acceptable hemodynamically mediated decline in glomerular filtration rate resulting from efferent arteriolar vasodilation.
Evidence-based -blockers (bisoprolol, carvedilol, and metoprolol succinate) carry a Class I recommendation and confer an approximate relative reduction in mortality and a reduction in hospitalizations (CIBIS II, COPERNICUS, MERIT-HF). Non-evidence-based agents (e.g., atenolol, metoprolol tartrate) lack demonstrated survival benefit, as demonstrated in the COMET trial where carvedilol proved superior to metoprolol tartrate. Carvedilol offers combined nonselective - and -adrenergic blockade, inducing peripheral vasodilation and greater systemic blood pressure reduction than metoprolol succinate. Initiation requires hemodynamic stability and absence of overt fluid retention. Starting doses are bisoprolol daily (target daily), carvedilol twice daily (target twice daily, or twice daily for weight ; controlled-release carvedilol daily titrated to daily), and metoprolol succinate to daily (target daily). Doses should be doubled every to . Fluid retention occurring during titration is managed by adjusting concomitant loop diuretics without discontinuing the -blocker unless frank cardiogenic shock ensues.
Mineralocorticoid receptor antagonists (spironolactone and eplerenone) carry a Class I recommendation for patients with Class II to IV symptoms to reduce morbidity and mortality (RALES, EMPHASIS-HF, EPHESUS). Spironolactone reduced all-cause mortality by and heart failure hospitalizations by in advanced heart failure, while eplerenone reduced cardiovascular death or heart failure hospitalization by in mild symptoms and mortality by post-myocardial infarction with systolic dysfunction. Initiation requires an and a baseline serum potassium of less than . For an , spironolactone is initiated at to daily (maintenance daily or twice daily) and eplerenone at daily (maintenance daily). For an of to , spironolactone is initiated at daily or every other day (maintenance to daily) and eplerenone at every other day (maintenance daily). Serum potassium and creatinine must be assessed at , , and post-initiation; doses must be reduced by or suspended if potassium exceeds . Gynecomastia occurs in approximately of patients receiving spironolactone due to nonselective binding to androgen and progesterone receptors; eplerenone provides a selective alternative devoid of endocrine adverse effects.
Sodium-glucose cotransporter 2 inhibitors (dapagliflozin once daily and empagliflozin once daily) represent foundational therapy (Class I) for symptomatic irrespective of diabetes status. The DAPA-HF and EMPEROR-Reduced trials confirmed marked reductions in cardiovascular death and heart failure hospitalizations. Dapagliflozin is initiated at an , and empagliflozin is indicated at an . Mechanisms include osmotic diuresis, natriuresis, reductions in preload and afterload, decreased intraglomerular pressure, enhanced myocardial energetics, and attenuation of cardiac fibrosis. Adverse event monitoring focuses on mycotic genital infections, volume contraction, orthostatic hypotension, and rare euglycemic diabetic ketoacidosis (), necessitating temporary drug cessation to prior to elective surgical procedures.
Loop diuretics inhibit to of sodium reabsorption in the thick ascending limb of the loop of Henle and are administered to achieve and maintain euvolemia (Class I). Oral bioavailability varies widely: furosemide displays erratic absorption ( to , average ), bumetanide exhibits to absorption, torsemide exhibits to absorption, and ethacrynic acid exhibits absorption. Bioequivalent oral doses are furosemide , bumetanide , torsemide to , and ethacrynic acid . Oral-to-intravenous conversion is for furosemide ( oral equals intravenous) and for bumetanide, torsemide, and ethacrynic acid. Ethacrynic acid represents the primary non-sulfa option for patients with true severe sulfonamide allergies. Daily dosing should aim for a weight reduction of to during active fluid congestion. Serum electrolytes must be closely tracked to maintain potassium at or greater and magnesium at or greater to protect against life-threatening ventricular arrhythmias.
Hydralazine and isosorbide dinitrate combination therapy carries a Class I recommendation to reduce morbidity and mortality in self-described African American patients with Class III to IV receiving optimal background therapy (A-HeFT; relative reduction in mortality) and a Class IIa recommendation in patients unable to tolerate an , inhibitor, or due to severe renal impairment or hyperkalemia. Dosing utilizes a fixed combination (BiDil: hydralazine / isosorbide dinitrate ) initiated at 1 tablet three times daily and titrated to a target of 2 tablets three times daily, or separate generic components titrated up to hydralazine and isosorbide dinitrate in divided doses. Hydralazine mediates arterial vasodilation (afterload reduction) and blunts nitrate tolerance through antioxidant mechanisms, while isosorbide dinitrate provides venous capacitance dilation (preload reduction). Adverse effects include headache, reflex tachycardia, hypotension, and dose-related drug-induced lupus erythematosus.
Ivabradine selectively inhibits the hyperpolarization-activated cyclic nucleotide-gated () inward funny current in the sinoatrial node, slowing the diastolic depolarization slope and lowering heart rate without affecting ventricular repolarization or contractility. It carries a Class IIa recommendation to reduce heart failure hospitalizations in patients with stable, symptomatic (), in sinus rhythm with a resting heart rate of or greater, who are receiving maximally tolerated doses of guideline-directed -blockers (SHIFT trial; reduction in cardiovascular death or heart failure hospitalization). Starting doses are twice daily with meals (or twice daily for age ), titrated after to to a maximum of twice daily for resting heart rate , maintained if heart rate is to , or reduced/discontinued if heart rate falls below . Notable adverse effects include visual luminous phenomena (phosphenes; ) and bradycardia or secondary atrial fibrillation ( to ). Ivabradine is contraindicated in acute decompensated heart failure, baseline blood pressure below , pre-initiation resting heart rate below , sinoatrial block, severe hepatic impairment (Child-Pugh Class C), and concurrent use of strong CYP3A4 inhibitors.
Digoxin exerts positive inotropy by reversibly inhibiting myocardial sodium-potassium adenosine triphosphatase () and modulates autonomic activity by sensitizing cardiac arterial baroreceptors to reduce central sympathetic outflow. In the DIG trial, digoxin produced a neutral effect on all-cause mortality but achieved a relative risk reduction in heart failure hospitalizations (Class IIb). Digoxin should be initiated without a loading dose in chronic heart failure at an oral maintenance dose of (or every other day in patients older than , those with renal dysfunction, or low lean body mass). Target serum trough concentrations are strictly maintained at to . Concentrations of or greater are linked to increased mortality, especially among women and older adults. Manifestations of digitalis toxicity (anorexia, nausea, vomiting, yellow-green visual chromatopsia, scotomas, heart block, and ventricular arrhythmias) are exacerbated by hypokalemia, hypomagnesemia, and hypercalcemia. Digoxin concentrations are elevated by concurrent administration of amiodarone (reduce digoxin dose by to ), dronedarone (reduce digoxin by ), verapamil, clarithromycin, erythromycin, itraconazole, posaconazole, cyclosporine, and tacrolimus.
Vericiguat is an oral soluble guanylate cyclase () stimulator that directly enhances cyclic guanosine monophosphate () production independently of endogenous nitric oxide () and sensitizes to residual endogenous , leading to smooth muscle relaxation and attenuation of myocardial and vascular remodeling. In the VICTORIA trial, vericiguat reduced the composite of cardiovascular death or heart failure hospitalization in high-risk patients with worsening () who experienced a recent heart failure hospitalization or required intravenous diuretics (Class IIb). Dosing begins at once daily with food and is titrated every through to a target of once daily, provided systolic blood pressure remains at or above . Vericiguat is teratogenic, contraindicated in pregnancy, and cannot be combined with phosphodiesterase type 5 () inhibitors or long-acting nitrates due to severe synergistic hypotension.
Additional supportive therapies include polyunsaturated fatty acids (), with prescription icosapent ethyl ( orally twice daily) or combined formulations ( daily containing of eicosapentaenoic acid and of docosahexaenoic acid) reasonable as adjunctive therapy to reduce cardiovascular death and hospitalizations (GISSI-HF, REDUCE-IT; Class IIb). Potassium-binding polymers, specifically patiromer (calcium-potassium exchanger; dose separated by from other oral medications; risk of hypomagnesemia) and sodium zirconium cyclosilicate (sodium/hydrogen-potassium exchanger; dose separated by from other oral medications; risk of sodium retention and edema), carry a Class IIb recommendation to manage recurrent hyperkalemia () and facilitate guideline-directed inhibitor and optimization (PEARL-HF, HARMONIZE). Primary prevention implantable cardioverter-defibrillators () are indicated (Class I) in patients with ischemic or nonischemic cardiomyopathy, an , and Class II to III symptoms on chronic optimal medical therapy with a life expectancy greater than , at least post-myocardial infarction, or post-infarct patients with an and Class I symptoms. Cardiac resynchronization therapy () is indicated for patients in sinus rhythm with an , left bundle branch block with a duration of or greater, and Class II to IV ambulatory symptoms on optimal therapy.
In , treatment targets blood pressure control (; Class I) and the management of fluid volume using diuretics (Class I). SGLT2 inhibitors carry a Class IIa recommendation based on clinical trials showing significant decreases in heart failure hospitalizations and cardiovascular mortality. , , and carry Class IIb recommendations to reduce hospitalizations, with benefits concentrated among patients with an at the lower end of the preserved spectrum ( to ; TOPCAT, PARAGON-HF, CHARM-Preserved). -Blockers are not recommended for in the absence of competing indications (such as prior myocardial infarction or rate control of atrial fibrillation) due to observational signals of increased heart failure hospitalizations. In , SGLT2 inhibitors hold a Class IIa recommendation for reducing mortality and hospitalizations, while , inhibitors, , evidence-based -blockers, and carry Class IIb recommendations. In , foundational pharmacotherapy must be continued indefinitely; the TRED-HF randomized withdrawal trial demonstrated that discontinuing neurohormonal therapies precipitates rapid relapse of left ventricular dysfunction and heart failure recurrence.
Cardiotoxic and destabilizing medications that must be avoided or used with caution in heart failure patients include: nonsteroidal anti-inflammatory drugs () and selective inhibitors, which promote sodium and water retention, induce afferent renal vasoconstriction, blunt diuretic responsiveness, and increase mortality; corticosteroids; minoxidil; thiazolidinediones (pioglitazone, rosiglitazone), which stimulate renal sodium reabsorption via peroxisome proliferator-activated receptor-gamma; Class Ia and Ic antiarrhythmics and dronedarone (which doubled mortality in decompensated heart failure); non-dihydropyridine calcium channel blockers (diltiazem, verapamil), which exert negative inotropic effects; itraconazole; dipeptidyl peptidase-4 () inhibitors saxagliptin and alogliptin, which increase heart failure hospitalizations; central nervous system stimulants and amphetamines; pregabalin (which induces peripheral edema); and cilostazol, a phosphodiesterase type 3 inhibitor that increases ventricular arrhythmias and mortality in .
Acute decompensated heart failure () manifests when compensatory mechanisms fail to preserve cardiac output and maintain normal filling pressures, often triggered by dietary nonadherence, medication omission, uncontrolled hypertension, acute myocardial ischemia, worsening mitral regurgitation, systemic infection, pulmonary embolism, alcohol or substance use, or development of tachyarrhythmias such as atrial fibrillation. Diagnostic evaluation relies on clinical assessment and serum natriuretic peptides. Heart failure is highly unlikely when is less than or is less than . Confirmatory cutpoints that establish heart failure diagnosis during acute dyspnea are age-stratified: for age younger than , for age to , and for age older than .
Hemodynamic profiling classifies patients into four clinical subsets according to volume status ("dry" vs. "wet") and systemic tissue perfusion ("warm" vs. "cold"). Congestion ("wet") reflects an elevated pulmonary capillary wedge pressure (), manifesting clinically as orthopnea, paroxysmal nocturnal dyspnea, jugular venous distension, hepatojugular reflux, pulmonary crackles, ascites, and peripheral edema. Hypoperfusion ("cold") reflects a depressed cardiac index (), presenting with cool extremities, narrowed pulse pressure, declining renal function, altered mentation, and fatigue. Subset I ("Warm and Dry"; normal filling pressures, adequate perfusion: to , ) represents compensated disease requiring outpatient oral optimization. Subset II ("Warm and Wet"; congestion with preserved perfusion) is the most common presentation, managed with intravenous loop diuretics alongside intravenous vasodilators (nitroglycerin, nitroprusside) in the absence of symptomatic hypotension (). Subset III ("Cold and Dry"; hypoperfusion without congestion: , ) requires cautious volume expansion with intravenous crystalloids to achieve an optimal filling pressure ( to ); if hypoperfusion persists once adequate preload is restored, inotropic support is initiated for an , or an arterial vasodilator is selected for an . Subset IV ("Cold and Wet"; combined congestion and hypoperfusion) represents cardiogenic decompensation, requiring aggressive intravenous loop diuresis paired with inotropes (dobutamine or milrinone) if , or intravenous arterial/venous vasodilators if .
In , pre-existing should be continued unless hemodynamic instability, cardiogenic shock, symptomatic bradycardia, or severe hyperkalemia supervenes. Withholding -blockers is associated with increased in-hospital and post-discharge mortality (OPTIMIZE-HF), though dose reduction or temporary suspension is necessary in cardiogenic shock or profound low-output states. Intravenous loop diuretic therapy should equal or exceed to the home oral dose administered as intravenous boluses or continuous infusion (e.g., outpatient furosemide twice daily converts to to intravenous furosemide twice daily). Diuretic resistance is addressed by escalating the loop diuretic dose toward ceiling thresholds ( to of intravenous furosemide), transitioning to a continuous infusion ( to , preceded by a loading bolus), or adding sequential nephron blockade with oral metolazone ( to given prior to the loop diuretic), intravenous chlorothiazide ( to daily), or intravenous acetazolamide ( daily targeting proximal tubule bicarbonate and sodium reabsorption).
Intravenous vasodilators provide rapid symptomatic relief in acute pulmonary congestion. Intravenous nitroglycerin acts primarily as a venous capacitance dilator at lower doses ( to 100\,\text{\mu g/min}) to lower , inducing modest arterial vasodilation only at higher infusion rates (up to 200\,\text{\mu g/min}); tachyphylaxis commonly develops within to . Sodium nitroprusside ( to 0.2\,\text{\mu g/kg/min}, titrated up to 10\,\text{\mu g/kg/min}) is a balanced arterial and venous vasodilator that decreases systemic vascular resistance () and ventricular filling pressures, demanding invasive arterial blood pressure monitoring to prevent profound hypotension; nitroprusside carries a risk of cyanide and thiocyanate toxicity, especially when infused for longer than or in patients with hepatic or renal impairment, and is avoided in myocardial infarction due to the risk of coronary steal. Intravenous inotropes (dobutamine, a - and -agonist dosed at to 20\,\text{\mu g/kg/min}; and milrinone, a phosphodiesterase type 3 inhibitor that prevents breakdown, dosed at to 0.75\,\text{\mu g/kg/min}) increase intracellular calcium and enhance contractility, but both increase ventricular arrhythmias and mortality. Milrinone relies on renal clearance () and has an elimination half-life of that extends to to in heart failure or renal dysfunction (and over in anuria), but remains effective during concomitant -blocker therapy due to its downstream mechanism. Dobutamine is favored in severe hypotension, severe renal dysfunction, or bradycardia, but loses efficacy in patients on chronic -blocker therapy. Oral tolvaptan ( daily, titrated to to ) is an oral selective vasopressin receptor antagonist indicated for hypervolemic or euvolemic hyponatremia (, or symptomatic hyponatremia refractory to fluid restriction); it must be initiated in the inpatient setting, carries a maximum rate of sodium correction of to per to avoid osmotic demyelination syndrome, and cannot be administered for longer than due to potential hepatotoxicity.
Acute Coronary Syndromes and Invasive Revascularization
Acute coronary syndrome () encompasses a clinical continuum spanning unstable angina (), non-ST-segment elevation myocardial infarction (), and ST-segment elevation myocardial infarction (). Pathophysiologically, the primary event in type 1 myocardial infarction involves atheromatous plaque disruption (rupture or erosion) that exposes subendothelial collagen and von Willebrand factor to flowing blood, triggering platelet adhesion, activation, and aggregation, followed by coagulation cascade activation and thrombus generation. Complete coronary thrombotic occlusion produces transmural ischemia manifested as , whereas partial occlusion, microembolization, or transient total occlusion produces non-ST-segment elevation acute coronary syndrome ().
Clinical presentation typically includes retrosternal chest discomfort described as crushing, squeezing, pressure, or tightness radiating to the left arm, neck, jaw, or epigastrium, frequently accompanied by diaphoresis, dyspnea, nausea, and lightheadedness. A significant proportion of myocardial infarctions, particularly in female, diabetic, and elderly patients, present without chest pain, manifesting as "angina equivalents" such as unexplained exertional dyspnea, profound fatigue, indigestion, or syncope. Diagnostic evaluation mandates acquisition and expert interpretation of a 12-lead electrocardiogram () within of first medical contact. Diagnostic criteria for require new ST-segment elevation measured at the J-point in two or more contiguous leads of at least (), except in precordial leads and , where sex- and age-specific thresholds apply. In , the may demonstrate ST-segment depression (), T-wave inversions (), or nonspecific ST-T abnormalities, or may appear normal. Serial high-sensitivity cardiac troponin ( or ) should be obtained at baseline and to later, or conventional troponins every to . Myocardial necrosis is confirmed when cardiac troponin concentrations exceed the 99th percentile upper reference limit () accompanied by a rising or falling kinetic pattern; elevated troponins differentiate from .

Risk stratification in guides the selection of an early invasive strategy versus an ischemia-guided (conservative) approach using validated clinical risk engines. The Thrombolysis in Myocardial Infarction () risk score compiles seven independent baseline variables (1 point each): age or older, three or more coronary artery disease risk factors, documented prior coronary stenosis of or greater, ST-segment deviation on presentation, two or more anginal episodes in the preceding , aspirin use within the prior , and elevated serum cardiac biomarkers. A score of to designates low risk, to intermediate risk, and to high risk of composite death, recurrent myocardial infarction, or severe ischemia within . The Global Registry of Acute Coronary Events () risk calculator estimates in-hospital and post-discharge mortality based on age, heart rate, systolic blood pressure, serum creatinine, Killip class, cardiac arrest at presentation, ST-segment deviation, and cardiac biomarkers, where a score greater than designates high risk favoring an early invasive strategy within . High-risk angiographic features contributing to procedural complexity include multivessel disease, left main or proximal left anterior descending artery involvement, chronic total occlusions, complex bifurcations, severe calcification, extreme tortuosity, and lesions exceeding in length.
In , primary percutaneous coronary intervention () is the reperfusion treatment of choice, provided it can be executed within a first medical contact-to-device door-to-balloon time of or less at a PCI-capable center, or within when interhospital transfer is required. Primary or emergent coronary artery bypass grafting () is indicated in complicated by cardiogenic shock irrespective of time delay from symptom onset. When transfer for primary cannot achieve balloon inflation within , fibrinolytic therapy must be administered within a door-to-needle time of or less, provided symptom onset occurred within the preceding and absolute contraindications are absent. Absolute contraindications to fibrinolytics include any prior intracranial hemorrhage, known structural cerebral vascular malformation (such as arteriovenous malformation), known malignant intracranial neoplasm, ischemic stroke within the preceding (excluding acute ischemic stroke within ), suspected aortic dissection, active internal bleeding or bleeding diathesis (excluding menses), significant closed-head or facial trauma within , intracranial or intraspinal surgery within , and severe uncontrolled hypertension refractory to acute emergency medical management. Relative contraindications comprise poorly controlled chronic hypertension, presentation blood pressure exceeding , history of ischemic stroke older than , prolonged or traumatic cardiopulmonary resuscitation (), major surgery within , recent internal hemorrhage ( to ), noncompressible vascular punctures, active peptic ulcer disease, current oral anticoagulant therapy, and pregnancy.
Fibrinolytic dosing regimens utilize fibrin-specific plasminogen activators: tenecteplase () is administered as a single weight-tiered intravenous bolus over (; to ; to ; to ; , equivalent to approximately ); alteplase () is administered as an accelerated, weight-adjusted infusion over ( intravenous push, followed by up to over , then up to over , maximum total dose for body weight ); and reteplase () is administered as a double bolus of intravenously followed by a second bolus later. Patients treated with fibrinolytics require concomitant full-dose parenteral anticoagulation for a minimum of and up to or until revascularization, using unfractionated heparin, weight-adjusted enoxaparin, or fondaparinux.
Initial acute anti-ischemic and analgesic therapy includes non-enteric-coated aspirin ( to chewed and swallowed immediately; Class I), which irreversibly acetylates platelet cyclooxygenase-1 () to suppress thromboxane generation. Sublingual nitroglycerin ( to every for up to three doses) is administered for ischemic chest pain, followed by continuous intravenous nitroglycerin (5\,\text{\mu g/min}, titrated up to 200\,\text{\mu g/min}) for ongoing ischemia, heart failure, or uncontrolled hypertension. Nitrates are strictly contraindicated within of sildenafil or vardenafil, within of tadalafil, in systolic blood pressure below or exceeding below baseline, severe bradycardia (), marked tachycardia ( in the absence of heart failure), or suspected right ventricular infarction. Supplemental oxygen is indicated only if arterial oxygen saturation () falls below ; hyperoxia in normoxic patients causes coronary vasoconstriction and is associated with increased myocardial injury and mortality. Intravenous morphine ( to every to ) provides analgesia and venodilation for refractory chest pain (Class IIb), but observational analyses (such as the CRUSADE registry) link morphine use to increased mortality, and pharmacokinetic studies demonstrate that morphine delays gastrointestinal absorption and diminishes peak antiplatelet activity of oral inhibitors. Oral -blockers should be initiated within the first in the absence of signs of heart failure, low-output states, risk factors for cardiogenic shock (age , heart rate , systolic blood pressure , prolonged duration of symptoms), or classic contraindications ( interval , second- or third-degree heart block, active bronchospastic airway disease). Intravenous -blockers should not be administered routinely due to an increased risk of cardiogenic shock.
Oral receptor antagonists are co-administered with aspirin to establish dual antiplatelet therapy () in all acute coronary syndrome presentations. Clopidogrel is an oral thienopyridine prodrug requiring two-step hepatic oxidation via cytochrome P450 enzymes (predominantly CYP2C19) to generate its active thiol metabolite, which irreversibly inhibits platelet receptors. Clopidogrel requires an oral loading dose of to ( achieves faster, more complete, and more consistent platelet inhibition within compared with for ), followed by a maintenance dose of daily. Clopidogrel carries a boxed warning regarding loss-of-function CYP2C19 alleles (*2, *3), which result in diminished active metabolite concentrations, attenuated platelet inhibition, and higher post-PCI ischemic and stent thrombosis rates; strong CYP2C19 inhibitors like omeprazole and esomeprazole should be avoided. Prasugrel is a third-generation thienopyridine prodrug rapidly hydrolyzed by intestinal esterases and converted by a single CYP-dependent step into an active metabolite that irreversibly inhibits receptors, providing more potent ( to inhibition) and faster antiplatelet activity (onset within ). Prasugrel is dosed as a oral loading dose followed by daily (reduced to daily for body weight or age ). Prasugrel holds a Class IIa recommendation over clopidogrel in ACS managed with based on the TRITON-TIMI 38 and ISAR-REACT 5 trials. However, prasugrel is strictly contraindicated in patients with a history of transient ischemic attack () or stroke due to a significant increase in intracranial and fatal bleeding; it should not be administered prior to defining coronary anatomy.
Ticagrelor is a direct-acting, reversibly binding, noncompetitive cyclopentyltriazolopyrimidine antagonist that does not require metabolic activation. Dosed as a oral loading dose followed by twice daily, ticagrelor achieves to platelet inhibition within . The PLATO trial demonstrated superiority over clopidogrel in reducing ischemic events and cardiovascular mortality without increasing overall major bleeding, though non-CABG bleeding was increased. Ticagrelor carries a boxed warning that maintenance aspirin doses exceeding decrease its clinical effectiveness; aspirin must be maintained at daily. Adverse effects unique to ticagrelor include dyspnea ( to ; mediated by adenosine reuptake inhibition) and asymptomatic ventricular pauses; caution is advised in severe pulmonary disease. Ticagrelor is contraindicated in active pathologic bleeding, history of intracranial hemorrhage, and severe hepatic impairment. Cangrelor is an intravenous, direct-acting, reversible antagonist with a plasma half-life of less than , achieving greater than platelet inhibition within when administered as a 30\,\text{\mu g/kg} intravenous bolus followed by a 4\,\text{\mu g/kg/min} continuous infusion for at least or the duration of (CHAMPION PHOENIX). Oral clopidogrel or prasugrel cannot be administered until the cangrelor infusion is terminated because cangrelor blocks their irreversible binding sites; ticagrelor may be loaded immediately before, during, or after cangrelor termination.
Intravenous glycoprotein IIb/IIIa () receptor inhibitors (eptifibatide and tirofiban) block the final common pathway of platelet aggregation by preventing fibrinogen cross-linking. Routine upstream administration before is not recommended due to increased bleeding without ischemic benefit; use is restricted to provisional bailout for large intraprocedural thrombus burden, slow-flow/no-reflow phenomena, or acute vessel closure in patients not adequately pretreated with oral inhibitors. Eptifibatide is dosed for as a double bolus of 180\,\text{\mu g/kg} intravenously apart, followed by a continuous infusion of 2.0\,\text{\mu g/kg/min} for to ; if creatinine clearance () is less than , the infusion is reduced by (1.0\,\text{\mu g/kg/min}), and it is avoided in hemodialysis. Tirofiban is dosed as a high-dose bolus of 25\,\text{\mu g/kg} over , followed by 0.15\,\text{\mu g/kg/min} for , with the infusion reduced by for .
Parenteral anticoagulation is indicated for all ACS patients throughout procedural revascularization. Unfractionated heparin () is administered as an initial weight-adjusted bolus of (maximum ) followed by a continuous infusion of (maximum ) titrated to institutional activated partial thromboplastin time () or anti-factor Xa ranges; during , target activated clotting times () are to (or to if concurrent inhibitors are used). Enoxaparin is dosed at subcutaneously every in (preceded by a intravenous bolus in high-risk patients); for , no supplemental anticoagulation is needed if the last subcutaneous dose was administered within , whereas an intravenous booster of is required if the last dose was given to prior. If , enoxaparin is adjusted to subcutaneously once daily. Fondaparinux ( subcutaneously daily) is a selective factor Xa inhibitor indicated for medical management of , but must never be used as the sole anticoagulant during (Class III: Harm) due to high rates of catheter thrombosis; supplemental (, or with inhibitors) must be co-administered during coronary intervention. Bivalirudin is an intravenous direct thrombin inhibitor dosed for as a bolus followed by a infusion, reduced to for and in hemodialysis. Bivalirudin is the anticoagulant of choice for patients with a documented history of heparin-induced thrombocytopenia () undergoing catheterization.
Long-term post-ACS medical therapy requires indefinite daily aspirin () and an oral inhibitor for at least (Class I), regardless of whether coronary stenting or medical therapy was employed. In patients treated with newer-generation drug-eluting stents (), early discontinuation of aspirin after to with continued inhibitor monotherapy (ticagrelor or clopidogrel) represents a reasonable strategy (Class IIa) to lower bleeding risks without increasing major adverse cardiovascular events (). In patients with high bleeding risk, discontinuing the inhibitor after while maintaining aspirin is reasonable (Class IIb). Conversely, prolonged beyond (up to ) using reduced-dose ticagrelor ( twice daily; PEGASUS-TIMI 54) or clopidogrel is reasonable for patients with high ischemic risk and low bleeding vulnerability. Decision-making is assisted by the validated DAPT score (calculated at post-PCI): a score of or greater favors prolonged by demonstrating a net ischemic benefit, whereas a score below portends an unfavorable risk profile driven by excess bleeding without reduction in ischemic outcomes.
Additional secondary prevention pharmacotherapies include: high-intensity statin therapy (atorvastatin daily or rosuvastatin to daily) initiated within of presentation, targeting an reduction of or greater and an absolute ; inhibitors (or ) initiated within and continued indefinitely in all patients with an , hypertension, diabetes, or stable chronic kidney disease; and aldosterone receptor antagonists (eplerenone or spironolactone) indicated in patients already taking an inhibitor and -blocker with an and either clinical heart failure symptoms or diabetes, provided serum potassium is less than and renal function is preserved ( in men, in women, or ; EPHESUS). For musculoskeletal pain, and selective inhibitors are strictly avoided (Class III: Harm); a stepped-care analgesic approach utilizing acetaminophen, nonacetylated salicylates, tramadol, or low-dose opioids should be employed.
In patients with atrial fibrillation undergoing , triple therapy (oral anticoagulant plus aspirin plus a inhibitor) significantly magnifies major bleeding and must be minimized. Large randomized clinical trials (WOEST, PIONEER AF-PCI, RE-DUAL PCI, AUGUSTUS) confirmed that double therapy consisting of a direct-acting oral anticoagulant () and a inhibitor (clopidogrel daily preferred; avoid prasugrel) without aspirin dramatically reduces major bleeding without increasing stent thrombosis or ischemic events compared to triple therapy. Aspirin is typically discontinued upon hospital discharge or continued for up to in patients with high thrombotic risk; after , antiplatelet therapy is discontinued and monotherapy is maintained indefinitely.
Chronic Coronary Disease and Angina Pectoris
Chronic coronary disease () describes stabilized outpatients with a prior history of acute coronary syndrome or coronary revascularization, patients with left ventricular systolic dysfunction or ischemic cardiomyopathy, individuals with stable angina, patients with vasospastic or microvascular angina, and asymptomatic individuals diagnosed via noninvasive imaging or coronary computed tomography angiography (). In the United States, approximately people live with coronary artery disease, and roughly carry an active diagnosis of . Therapeutic goals are twofold: prolong survival by preventing recurrent myocardial infarction, heart failure hospitalizations, and cardiovascular death, and enhance quality of life by preventing anginal symptoms and restoring functional exercise capacity.
Lifestyle interventions require at least of moderate-intensity aerobic physical activity or at least of vigorous-intensity aerobic exercise, combined with resistance training on at least . Nutritional guidance mandates adherence to a Mediterranean or dietary pattern emphasizing fresh fruits, vegetables, legumes, whole grains, nuts, and lean animal or plant proteins, while eliminating industrial trans fats, limiting saturated fats to less than of total daily calories, and restricting dietary sodium to less than (optimally ). Over-the-counter dietary supplements, including non-purified omega-3 fish oils, vitamin E, vitamin C, and beta-carotene, lack demonstrated efficacy for cardiovascular event reduction.

Antithrombotic therapy in without an indication for chronic anticoagulation is guided by time elapsed from revascularization and individual ischemic versus bleeding risk. For patients with stable without recent () or prior , single antiplatelet therapy () with low-dose aspirin ( to daily, typically in the United States) is recommended. The PANTHER individual patient-data meta-analysis established that long-term inhibitor monotherapy (predominantly clopidogrel daily) provides equivalent bleeding rates and a significant reduction in compared with aspirin monotherapy, supporting clopidogrel as an effective alternative. Routine addition of clopidogrel to aspirin in patients with stable lacking recent or stenting is not recommended due to bleeding risks without clinical benefit. In patients with at high risk of recurrent ischemic events and low bleeding risk who lack an indication for full anticoagulation or , the addition of vascular-dose rivaroxaban ( orally twice daily) to aspirin daily is reasonable to reduce based on the COMPASS trial ( reduction in cardiovascular death, stroke, or myocardial infarction offset by increased major bleeding without significant difference in fatal bleeding).

In patients with who require therapeutic anticoagulation (e.g., for atrial fibrillation or venous thromboembolism) and undergo with a drug-eluting stent, antithrombotic duration is stratified by clinical risk. In patients with low-to-moderate bleeding risk, triple therapy with a , clopidogrel ( daily), and aspirin ( daily) is restricted to the peri-procedural period (up to post-PCI), transitioning to double therapy ( plus clopidogrel) through month 6 or 12, followed by lifelong monotherapy. In patients with high ischemic risk, triple therapy is continued for up to , followed by double therapy through month 6 or 12, and monotherapy beyond . In patients with stable on therapeutic anticoagulation who did not undergo , oral anticoagulant monotherapy with a is recommended without antiplatelet co-administration.

Antianginal medical therapy aims to rebalance myocardial oxygen supply and demand. First-line therapies for symptom control include -blockers, calcium channel blockers (), or long-acting nitrates. All patients must receive a prescription for sublingual nitroglycerin tablets ( to ) or nitroglycerin lingual spray for acute symptom termination or situational prophylaxis before exertion. Nitroglycerin lingual spray demonstrates faster mucosal absorption, more reliable clinical efficacy, and fewer tension headaches than sublingual tablets. -Blockers reduce myocardial oxygen consumption by reducing resting and exercise heart rate, myocardial contractility, and systemic arterial pressure; in patients with a history of myocardial infarction, -blockers are prioritized during the initial and maintained indefinitely if left ventricular systolic dysfunction () or symptomatic heart failure is present. Calcium channel blockers promote epicardial coronary vasodilation and afterload reduction; dihydropyridines (amlodipine, felodipine) are preferred when combined with -blockers, whereas non-dihydropyridines (diltiazem, verapamil) reduce heart rate and contractility and must be used with caution alongside -blockers due to risks of sinus arrest and high-grade atrioventricular block. Long-acting oral nitrates (isosorbide mononitrate, isosorbide dinitrate) provide venodilation, lower ventricular preload, and promote coronary collateral blood flow; an eccentric dosing schedule providing a daily nitrate-free interval of to is mandatory to avoid vascular tolerance.
Ranolazine serves as a third-line antianginal agent for patients with persistent symptoms despite optimized -blocker, , and nitrate therapy, or as a second-line agent when hemodynamic parameters (bradycardia or hypotension) preclude dose escalation of first-line therapies. Ranolazine selectively inhibits the late phase of the inward sodium current () in ischemic ventricular cardiomyocytes. Attenuating excess intracellular sodium influx prevents reverse-mode activation of the sodium-calcium exchanger (), decreasing intracellular calcium overload, improving diastolic left ventricular relaxation, reducing microvascular compression, and enhancing myocardial oxygen efficiency without altering heart rate or systemic blood pressure. Ranolazine produces dose-dependent prolongation of the corrected QT () interval and is metabolized via CYP3A4 and cleared as a P-glycoprotein () substrate. It is contraindicated in severe hepatic cirrhosis, and concurrent administration with strong CYP3A4 inhibitors (ketoconazole, clarithromycin) or inducers (rifampin, carbamazepine, St. John's wort) is prohibited; when co-administered with moderate CYP3A4 inhibitors (diltiazem, verapamil, fluconazole), the ranolazine dose must not exceed twice daily.

Blood pressure in is managed to a goal below . Initial pharmacotherapy combines an inhibitor or with an evidence-based -blocker for patients with recent myocardial infarction, left ventricular systolic dysfunction (), or active angina. If blood pressure remains elevated (), dihydropyridine calcium channel blockers, thiazide-like diuretics (chlorthalidone), or mineralocorticoid receptor antagonists are added sequentially. In patients with and an , metoprolol succinate, carvedilol, or bisoprolol are specifically prioritized. In patients with a remote history of myocardial infarction () who lack left ventricular systolic dysfunction (), ongoing angina, arrhythmias, or uncontrolled hypertension, the necessity of continuing -blocker therapy should be reassessed.

Lipid management in dictates that all patients receive maximally tolerated high-intensity statin therapy (atorvastatin or rosuvastatin to daily) to achieve a baseline reduction of or greater and an absolute target below . Risk stratification classifies individuals into very high risk if they possess a history of multiple major events (recent acute coronary syndrome within , prior myocardial infarction, ischemic stroke, or symptomatic peripheral artery disease) or one major event plus multiple high-risk conditions (age , heterozygous familial hypercholesterolemia, history of prior or outside the index event, diabetes mellitus, hypertension, chronic kidney disease with to , active tobacco smoking, heart failure, or persistently elevated despite statins and ezetimibe). If remains at or above on maximally tolerated statin therapy, ezetimibe ( daily) is added; if remains at or above or non-HDL-C is or greater on statin plus ezetimibe, a proprotein convertase subtilisin/kexin type 9 () monoclonal antibody (evolocumab or alirocumab) should be initiated. For patients with statin intolerance or inadequate response, bempedoic acid (which demonstrated significant reduction in the CLEAR Outcomes trial) or inclisiran may be incorporated. When fasting triglycerides remain elevated ( to ) despite statin therapy, icosapent ethyl ( twice daily with meals) is added to reduce ischemic cardiovascular events (REDUCE-IT).
Sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 () receptor agonists confer cardioprotective benefits in patients with . SGLT2 inhibitors carry a strong recommendation in patients with concurrent type 2 diabetes or heart failure (irrespective of ejection fraction) to reduce , cardiovascular death, and heart failure hospitalizations. GLP-1 receptor agonists (such as subcutaneous semaglutide and liraglutide) are recommended in patients with and type 2 diabetes to decrease , and are indicated as adjuncts for weight reduction in patients with overweight or obesity to improve metabolic control and reduce cardiovascular risk. Secondary prevention also incorporates routine immunizations (annual influenza, pneumococcal, and COVID-19 vaccinations), anti-inflammatory secondary prevention with low-dose colchicine ( daily) to suppress atherothrombotic events, complete tobacco cessation, elimination of excess alcohol, and structured screening and treatment for clinical depression.
Atrial Fibrillation and Arrhythmia Management
Atrial fibrillation () represents the most common sustained cardiac arrhythmia encountered in clinical practice, affecting over Americans. The arrhythmia is characterized electrophysiologically by rapid, disorganized, and chaotic atrial activation, resulting in mechanical dyssynchrony of the atrial myocardium and an irregularly irregular ventricular response.

In normal cardiac conduction, the cardiac impulse originates spontaneously in the sinoatrial () node located in the superior right atrium, propagates across atrial tissue, pauses within the atrioventricular () node to ensure ventricular filling, traverses the bundle of His, bifurcates down the right and left bundle branches, and rapidly distributes through the subendocardial Purkinje arborization to activate ventricular myocardium. In atrial fibrillation, multiple disorganized wavelets of functional reentry or rapidly firing ectopic foci (most commonly originating within the muscular sleeves of the pulmonary veins in the left atrium) bombard the node at rates ranging from to . The node acts as a physiological filter; its decremental conduction and variable refractory period permit only a fraction of these chaotic impulses to activate the ventricles, yielding an irregularly irregular ventricular response and an absent atrial "kick," which reduces cardiac output by to .

Electrocardiographic hallmarks of atrial fibrillation consist of an irregularly irregular interval pattern, the absence of distinct, uniform P waves, and their replacement by rapid, irregular fibrillatory (f) waves varying in amplitude, morphology, and timing. Clinical classifications define paroxysmal as recurrent episodes that terminate spontaneously or with intervention within of onset; persistent as continuous episodes lasting longer than ; long-standing persistent as continuous episodes exceeding where a rhythm control strategy is maintained; and permanent where patient and clinician mutually decide to cease further rhythm restoration attempts, accepting the arrhythmia as permanent. Nonvalvular is clinically defined by the absence of moderate-to-severe mitral stenosis or a mechanical prosthetic heart valve. Predisposing etiologies encompass conditions causing atrial stretch or structural remodeling (chronic hypertension, mitral or tricuspid valvular disease, cardiomyopathies, pulmonary hypertension, acute pulmonary embolism, obstructive sleep apnea, chronic obstructive pulmonary disease) and triggers of hyperadrenergic tone (thyrotoxicosis, sepsis, alcohol intoxication or withdrawal, major cardiothoracic surgery, and sympathomimetic exposures).
Initial pharmacotherapy addresses ventricular rate control. Resting heart rate targets are stratified: a strict rate-control goal ( at rest) is reasonable for symptomatic patients (Class IIa), whereas a lenient rate-control strategy ( at rest) is acceptable for asymptomatic patients with preserved ejection fraction (AFFIRM, RACE; Class IIb). First-line rate-controlling agents include -blockers and non-dihydropyridine calcium channel blockers (). -Blockers (metoprolol, carvedilol, atenolol, bisoprolol) slow nodal conduction velocity and prolong refractory periods, performing effectively during physical exertion and hyperadrenergic states; carvedilol, metoprolol succinate, and bisoprolol are specifically indicated in patients with comorbid . Non-dihydropyridine (diltiazem, verapamil) inhibit L-type calcium channels within the node to provide rate control during rest and exercise, making them useful in chronic obstructive pulmonary disease or asthma, but are contraindicated in left ventricular systolic dysfunction () due to negative inotropic effects. Digoxin slows nodal conduction primarily via central vagomimetic effects; it is ineffective as monotherapy for rate control during exercise due to high sympathetic tone, but serves as a useful adjunctive agent in or sedentary patients. Intravenous amiodarone is reserved for acute rate control in patients with critical illness, severe left ventricular systolic dysfunction, or heart failure without an accessory pathway when alternative agents are ineffective or contraindicated.
A rhythm control strategy aims to restore and maintain normal sinus rhythm through electrical or pharmacologic cardioversion, antiarrhythmic drug () therapy, or catheter ablation. The EAST-AFNET 4 trial established that early rhythm control initiated within of diagnosis in patients with cardiovascular comorbidities resulted in a significant reduction in cardiovascular death, stroke, and heart failure hospitalizations compared with rate control alone. Pharmacologic cardioversion is achieved using Vaughan-Williams Class Ic (flecainide, propafenone) or Class III (amiodarone, dofetilide, ibutilide) antiarrhythmic agents.
Cardioversion carries an inherent risk of thromboembolism due to the mobilization of pre-existing atrial thrombi or post-cardioversion atrial stunning. For patients presenting with atrial fibrillation of or greater duration, or when the duration is unknown, therapeutic anticoagulation must be administered continuously for at least prior to elective cardioversion, followed by mandatory therapeutic anticoagulation for at least post-cardioversion, irrespective of the patient's baseline stroke risk score. Alternatively, an expedited transesophageal echocardiogram () strategy may be employed: full therapeutic anticoagulation (using unfractionated heparin, low-molecular-weight heparin, or a ) is initiated, and if confirms the absence of thrombus in the left atrium and left atrial appendage, cardioversion is executed within , followed by at least of therapeutic oral anticoagulation. For hemodynamically unstable atrial fibrillation (severe hypotension, cardiogenic shock, acute pulmonary edema, ongoing myocardial ischemia), immediate synchronized direct-current cardioversion is indicated, with therapeutic parenteral anticoagulation administered immediately prior to the shock and maintained for at least post-procedure.
Antiarrhythmic drug selection is dictated by the presence or absence of underlying structural heart disease (defined as coronary artery disease, prior myocardial infarction, left ventricular hypertrophy, or heart failure). Class Ic agents (flecainide and propafenone) exhibit fast sodium channel blockade with slow dissociation kinetics, slowing conduction velocity without prolonging the refractory period or the QT interval. In the absence of structural heart disease, flecainide ( to twice daily) and propafenone ( to every to , or extended-release to twice daily) provide to efficacy for sinus rhythm maintenance; a "pill-in-the-pocket" strategy utilizing a single oral dose of flecainide ( to ) or propafenone ( to ) can terminate paroxysmal out-of-hospital episodes. Class Ic agents can convert atrial fibrillation into rapid atrial flutter with conduction; therefore, concomitant nodal blocking agents (-blockers or non-dihydropyridine ) must be prescribed. Class Ic agents are strictly contraindicated in structural heart disease or ischemic coronary disease based on the CAST trial, which demonstrated increased mortality driven by fatal ventricular proarrhythmias.
Class III antiarrhythmics block delayed rectifier potassium channels to prolong action potential duration and effective refractoriness, manifesting on the surface as QT interval prolongation. Amiodarone exhibits multichannel electrophysiologic properties (Classes I, II, III, IV) and represents the most effective agent for sinus rhythm maintenance ( to efficacy). Because of its neutral mortality profile in left ventricular systolic dysfunction, amiodarone is safe in coronary disease and heart failure. Oral loading requires cumulative administration of to (typically two to three times daily for , followed by daily for , then daily maintenance). Its terminal elimination half-life averages approximately to , reflecting extensive lipophilic tissue sequestration. Amiodarone is a potent inhibitor of CYP3A4, CYP2C9, CYP2D6, CYP1A2, and P-glycoprotein, requiring empiric dose reductions of concomitant warfarin (decrease by to ), digoxin (decrease by ), simvastatin (maximum daily dose ), and lovastatin (maximum daily dose ). Extracardiac organ toxicities require baseline and periodic surveillance: serum transaminases and thyroid function panels every ; annual chest radiography; baseline pulmonary function testing with diffusing capacity of the lungs for carbon monoxide () repeated for unexplained cough or dyspnea (pulmonary toxicity/interstitial pneumonitis); ophthalmologic exams for visual changes (corneal microdeposits, optic neuritis); and monitoring for photosensitivity, blue-gray skin discoloration, peripheral neuropathy, and ataxia.
Sotalol is a nonselective -blocker with class III potassium channel blocking properties ( activity), indicated for sinus rhythm maintenance in patients with coronary disease or hypertension without significant left ventricular hypertrophy or heart failure. Sotalol is contraindicated in heart failure (), baseline , and . Initiation requires a mandatory minimum hospitalization with continuous telemetry monitoring and serial . Dosing is adjusted for creatinine clearance: twice daily for , and once daily for to . If the exceeds during therapy, the dose must be decreased or the drug discontinued to avoid torsades de pointes.
Dofetilide is a pure selective blocker of the rapid component of the delayed rectifier potassium current (), devoid of negative inotropic or hemodynamic effects, making it safe for sinus rhythm restoration and maintenance in heart failure and coronary disease. Dofetilide requires mandatory inpatient initiation for a minimum of (5 doses) with continuous cardiac telemetry and renal surveillance. Starting doses are calculated strictly from estimated creatinine clearance: 500\,\text{\mu g} orally twice daily for ; 250\,\text{\mu g} twice daily for to ; 125\,\text{\mu g} twice daily for to ; and contraindicated for . Baseline must not exceed ( in intraventricular conduction delays). A repeat must be obtained to following the initial dose; if the increases by greater than over baseline or exceeds ( in ventricular conduction delay), the dose must be reduced by . If the exceeds at any check during subsequent doses, the drug must be discontinued. Dofetilide is cleared via renal cationic transport; co-administration is contraindicated with cimetidine, verapamil, hydrochlorothiazide, trimethoprim (alone or with sulfamethoxazole), ketoconazole, itraconazole, prochlorperazine, megestrol, and dolutegravir.
Dronedarone is a non-iodinated synthetic derivative of amiodarone that undergoes CYP3A4 hepatic clearance with an elimination half-life of to . Dosed at orally twice daily with morning and evening meals, dronedarone reduces cardiovascular hospitalizations in paroxysmal or persistent . Dronedarone carries boxed warnings and is strictly contraindicated in patients with permanent atrial fibrillation (PALLAS trial; doubled risk of stroke, heart failure hospitalizations, and cardiovascular death) and in symptomatic heart failure with recent decompensation or Class IV symptoms (ANDROMEDA trial; doubled mortality). Dronedarone inhibits tubular creatinine secretion, producing a benign, reversible rise in serum creatinine of approximately without reducing true glomerular filtration.
Thromboembolic risk stratification in nonvalvular atrial fibrillation utilizes the validated score:
Congestive heart failure or :
Hypertension:
Age or older:
Diabetes mellitus:
Stroke, , or systemic thromboembolism:
Vascular disease (prior myocardial infarction, peripheral arterial disease, or complex aortic plaque):
Age to :
Sex category (female):
For patients with a score of in men or in women, it is reasonable to omit oral anticoagulant therapy. For a score of in men or in women, oral anticoagulation may be considered based on clinical shared decision-making. For a score of or greater in men or or greater in women, chronic oral anticoagulation is indicated (Class I). Direct-acting oral anticoagulants (: dabigatran twice daily; rivaroxaban once daily with the evening meal; apixaban twice daily, or twice daily if any two of: age , body weight , or serum creatinine ; edoxaban once daily) are recommended over warfarin due to superior efficacy, lower rates of intracranial hemorrhage, and absent dietary monitoring requirements. Warfarin (titrated to an of to ) remains the agent of choice for valvular atrial fibrillation (moderate-to-severe mitral stenosis or mechanical heart valves).
Acute Life-Threatening Arrhythmias and Cardiac Arrest
Adult cardiac arrest management follows the Advanced Cardiovascular Life Support () algorithmic framework, dividing arrest presentations into shockable rhythms (ventricular fibrillation [] and pulseless ventricular tachycardia []) and non-shockable rhythms (asystole and pulseless electrical activity []). Resuscitation requires immediate cardiopulmonary resuscitation () with chest compressions delivered at a rate of to and a depth of to , minimizing interruptions, avoiding hyperventilation, and providing high-flow oxygen.
For shockable rhythms (), an initial asynchronous defibrillation shock is delivered ( to for biphasic waveforms, or for monophasic), followed immediately by of continuous without pausing for rhythm checks. Following the second defibrillation shock, epinephrine ( intravenously or intraosseously) is administered every to . If ventricular fibrillation or pulseless ventricular tachycardia persists following the third defibrillation shock, an antiarrhythmic drug is administered: amiodarone is the drug of choice, dosed as a first intravenous bolus of diluted in of dextrose in water () or normal saline, with an optional repeat bolus of administered once for refractory shockable arrest. If amiodarone is unavailable, lidocaine serves as an alternative, dosed at to intravenous push initial bolus, followed by repeat doses of to every to up to a maximum cumulative dose of . For non-shockable rhythms (), immediate defibrillation is not indicated; management focuses on continuous high-quality , rapid intravenous/intraosseous administration of epinephrine every to , and prompt identification and reversal of underlying etiologies (the "H's and T's": hypovolemia, hypoxia, hydrogen ion acidosis, hypokalemia or hyperkalemia, hypothermia, tension pneumothorax, cardiac tamponade, toxins, pulmonary thrombosis, and coronary thrombosis).
Post-resuscitation care for comatose adult patients who achieve return of spontaneous circulation () incorporates Targeted Temperature Management () to optimize neurological recovery. Clinical guidelines recommend maintaining a constant core body temperature between and (or strict active normothermia avoiding fever, supported by TTM and TTM2 trials) for at least , followed by controlled rewarming at a rate of . Thermoregulatory shivering, which increases metabolic heat production by up to and elevates systemic oxygen consumption, must be controlled using buspirone, meperidine, clonidine, dexmedetomidine, or neuromuscular blocking infusions. Deep sedation and analgesia are maintained using continuous fentanyl, midazolam, or propofol. Induced hypothermia impairs insulin secretion and peripheral sensitivity (requiring insulin infusions to maintain glycemic targets of to ), suppresses renal tubular reabsorption (causing cold diuresis and hypokalemia during cooling, with rebound hyperkalemia during rewarming), and impairs enzymatic clotting pathways, demanding surveillance of platelet counts, , and .
In acute symptomatic bradycardia, unstable signs (hypotension, acutely altered mental status, ischemic chest discomfort, acute pulmonary edema, or cardiogenic shock) warrant immediate administration of atropine ( intravenously every to , up to a maximum cumulative dose of ). If atropine is ineffective or contraindicated (e.g., in Mobitz Type II second-degree or third-degree atrioventricular block with wide , or denervated heart post-transplantation), transcutaneous pacing should be initiated immediately, supported by continuous infusions of dopamine ( to 20\,\text{\mu g/kg/min}) or epinephrine ( to 10\,\text{\mu g/min}) titrated to chronotropic and hemodynamic response.
In acute symptomatic tachycardia, unstable manifestations mandate emergent synchronized electrical cardioversion. In stable tachycardia, management is stratified by duration. Narrow-complex tachycardia () with a regular rhythm represents supraventricular tachycardia () or sinus tachycardia, treated initially with vagal maneuvers followed by rapid intravenous administration of adenosine: rapid intravenous push through a large peripheral vein followed immediately by a saline flush and arm elevation; if sinus conversion does not occur within to , a second dose of is administered (repeatable once). The initial dose of adenosine is reduced to in patients receiving dipyridamole or carbamazepine, in heart transplant recipients, or when administering via a central venous catheter; higher doses may be needed in the presence of methylxanthines (theophylline, caffeine). Adenosine is contraindicated in severe bronchospastic asthma and must never be administered for irregular or polymorphic wide-complex tachycardia due to the risk of precipitating ventricular fibrillation. Regular narrow-complex refractory to adenosine is managed with intravenous non-dihydropyridine (diltiazem IV over , followed by to ) or intravenous -blockers (esmolol, metoprolol).
Wide-complex tachycardia () should be treated as ventricular tachycardia () until proven otherwise. Stable monomorphic is managed with intravenous antiarrhythmic infusions: procainamide ( IV infusion up to a maximum loading dose of , discontinued if the arrhythmia terminates, severe hypotension occurs, or widens by ; maintenance to ), amiodarone ( IV over , repeated as needed, followed by for , then for ), or sotalol ( IV over ). Procainamide is contraindicated in severe heart failure () or baseline prolonged QT; sotalol is contraindicated in heart failure or . In pre-excited atrial fibrillation (Wolff-Parkinson-White syndrome with antegrade conduction down an accessory pathway), all nodal blocking agents (-blockers, diltiazem, verapamil, digoxin, adenosine) are strictly contraindicated because preferential conduction down the accessory pathway can accelerate the ventricular rate and degenerate into ventricular fibrillation; intravenous procainamide is the drug of choice. Polymorphic ventricular tachycardia associated with a prolonged baseline QT interval (torsades de pointes) is managed in stable patients with intravenous magnesium sulfate ( to IV diluted in over , repeatable up to per ), correction of hypokalemia ( to ), withdrawal of offending QT-prolonging medications, and overdrive pacing; unstable polymorphic requires immediate unsynchronized defibrillation.
Hypertension: Chronic Management and Hypertensive Crises
Hypertension is defined as a persistent, nonphysiologic elevation of systemic arterial pressure, specifically a systolic blood pressure () of or greater, or a diastolic blood pressure () of or greater. Approximately of adult Americans are affected, establishing hypertension as a leading modifiable risk factor for stroke, myocardial infarction, heart failure, chronic kidney disease, and vascular mortality. Essential (primary) hypertension accounts for of all clinical diagnoses, arising from complex multifactorial interactions between genetic susceptibility and environmental factors (obesity, excess dietary sodium, physical inactivity). Secondary hypertension accounts for approximately of cases and must be investigated in severe, resistant, or abrupt-onset disease; primary causes include primary aldosteronism, renal parenchymal disease, renovascular hypertension (renal artery stenosis), obstructive sleep apnea, Cushing syndrome, hyperthyroidism or hypothyroidism, hyperparathyroidism, pheochromocytoma, and medications (cyclosporine, tacrolimus, , oral contraceptives containing estrogen, systemic corticosteroids, sympathomimetics, and angiogenesis inhibitors).
Diagnosis requires proper measurement methodology. Patients must remain seated quietly in a chair with back supported and feet flat on the floor for at least , refraining from caffeine, exercise, and smoking for at least prior to testing. An appropriately sized cuff must be used (bladder length encircling at least of arm circumference and width encircling at least ). Blood pressure must be obtained at least twice, separated by at least , and averaged. Establishing a formal diagnosis requires documenting elevated average readings across two or more separate clinical encounters. Out-of-office blood pressure confirmation using 24-hour ambulatory blood pressure monitoring () or home blood pressure monitoring () is recommended to identify white-coat hypertension (office to , but daytime or after a lifestyle trial) and masked hypertension (office to , but daytime out-of-office ).
Nonpharmacologic lifestyle modifications provide substantial, dose-dependent reductions in systolic blood pressure and are recommended for all clinical categories: maintaining a normal body mass index ( to ) reduces by to per of weight loss; adopting the Dietary Approaches to Stop Hypertension () diet (rich in fruits, vegetables, low-fat dairy products, and dietary potassium, with reduced saturated and total fat) reduces by to ; reducing dietary sodium consumption to less than (or a minimum reduction of ) lowers by to ; participating in structured aerobic exercise (at least of brisk walking most days) reduces by to ; and moderating alcohol consumption (limiting intake to or fewer standard drinks daily in men and or fewer standard drinks daily in women) reduces by to .
The 2017 guidelines define four blood pressure categories in adults:
Normal: and
Elevated: to and
Stage 1 Hypertension: to or to
Stage 2 Hypertension: or

Thresholds for initiating pharmacotherapy and blood pressure targets are defined by clinical cardiovascular disease status and calculated risk. For patients with established clinical or a calculated 10-year risk of or greater, the threshold for pharmacotherapy is a blood pressure of or greater, with a treatment goal of less than . For individuals without clinical whose 10-year risk is below , the threshold is or greater, with a treatment goal of less than . Compelling comorbid conditions—including diabetes mellitus, chronic kidney disease, post-renal transplantation, heart failure, and stable ischemic heart disease—mandate a threshold of or greater and a goal below . For ambulatory, noninstitutionalized community-dwelling adults aged or older, the treatment threshold is an of or greater, targeting an below , supported by the SPRINT trial where intensive lowering ( vs. ) reduced primary composite major cardiovascular events and all-cause mortality, even among patients older than .
Pharmacologic selection for Stage 1 hypertension with an indication for treatment typically begins with a single first-line agent selected from four primary classes: thiazide or thiazide-like diuretics, dihydropyridine calcium channel blockers, inhibitors, or . In adults presenting with Stage 2 hypertension and an average blood pressure greater than above target, initial pharmacotherapy should combine two first-line agents of different classes, administered as separate components or a fixed-dose combination. Specific comorbidity-directed indications apply: in chronic kidney disease with albuminuria ( or albumin-to-creatinine ratio), inhibitors or are preferred first-line agents to slow renal disease progression; in diabetes with persistent albuminuria, inhibitors or are indicated; in Black adults without heart failure or chronic kidney disease, initial therapy should include a thiazide-type diuretic or a calcium channel blocker due to enhanced blood pressure lowering efficacy compared to monotherapy; in pregnant women, preferred agents are oral labetalol, nifedipine extended-release, or methyldopa, while inhibitors, , and direct renin inhibitors (aliskiren) are contraindicated due to severe fetotoxicity and congenital malformations.
Resistant hypertension is defined as an office blood pressure of or greater in a patient confirmed adherent to at least three antihypertensive medications of different pharmacologic classes at optimal doses, one of which must be a diuretic; or an office blood pressure controlled to less than requiring four or more concurrent antihypertensive drugs. Evaluation mandates exclusion of pseudoresistance (inaccurate cuff sizing, white-coat effect, medication nonadherence) and identification of interfering substances (, oral decongestants, systemic steroids, cocaine, amphetamines). Pharmacologic optimization of resistant hypertension requires maximizing diuretic efficacy: substituting chlorthalidone or indapamide for hydrochlorothiazide in patients with preserved renal function () due to longer half-lives and enhanced natriuresis, or switching to loop diuretics (furosemide, torsemide) if . The definitive next pharmacologic step is the addition of a mineralocorticoid receptor antagonist (spironolactone to daily, or eplerenone) to provide distal tubule aldosterone blockade, followed by the sequential addition of -blockers, centrally acting -agonists, or direct vasodilators (hydralazine or minoxidil, which require concomitant -blockers and loop diuretics to suppress reflex tachycardia and severe sodium retention).
Hypertensive crises are defined by severe elevations in arterial pressure, typically exceeding systolic or diastolic. A hypertensive emergency is characterized by severe blood pressure elevation accompanied by acute, progressive target-organ damage (hypertensive encephalopathy, intracranial hemorrhage, acute ischemic stroke, acute aortic dissection, acute myocardial infarction, acute pulmonary edema with left ventricular failure, acute renal failure, microangiopathic hemolytic anemia, or eclampsia). Immediate admission to an intensive care unit and parenteral antihypertensive titration is mandatory. The general therapeutic goal is to reduce mean arterial pressure () by no more than within the first hour; if stable, is lowered to and to to over the subsequent to , with gradual normalization achieved over the following to . Excessive or precipitous blood pressure reduction must be avoided to prevent cerebral, renal, or coronary hypoperfusion caused by shifted vascular autoregulation curves.
Specific compelling clinical conditions dictate distinct blood pressure targets in hypertensive emergency:
Acute aortic dissection: Systolic blood pressure must be reduced to less than and heart rate below within the first . Intravenous -blockers (esmolol, labetalol) must be administered prior to vasodilators (nitroprusside, nicardipine) to suppress reflex tachycardia and reduce aortic wall shear stress ().
Severe preeclampsia or eclampsia, or pheochromocytoma crisis: Systolic blood pressure should be rapidly lowered to less than within the first hour of treatment.
Acute ischemic stroke: Blood pressure is not lowered acutely unless the patient is a candidate for intravenous thrombolysis (where blood pressure must be reduced to prior to fibrinolysis and maintained below for ) or presents with extreme hypertension ( or , where an initial reduction over is targeted).
Acute intracranial hemorrhage: In patients presenting with an between and , acute reduction of to less than within the first hours provides no clinical benefit and can worsen cerebral perfusion; continuous intravenous infusions (nicardipine, clevidipine, labetalol) should be utilized to control smoothly while avoiding agents that increase intracranial pressure (hydralazine, nitroprusside, nitroglycerin).
Intravenous pharmacologic agents used in hypertensive emergencies include:
Nicardipine: A dihydropyridine calcium channel blocker administered at , titrated by every to to a maximum of . It provides predictable arterial vasodilation without affecting cardiac conduction, making it a first-line option across diverse presentations, but is contraindicated in severe aortic stenosis.
Clevidipine: An ultrashort-acting dihydropyridine calcium channel blocker formulated in a lipid emulsion, metabolized by vascular and blood esterases with an elimination half-life of to . Initiated at to , the dose is doubled every until approaching goal, then titrated up to . It is contraindicated in patients with severe egg or soybean allergies, advanced aortic stenosis, or severe hyperlipidemia.
Labetalol: A combined - and nonselective -adrenergic antagonist ( ratio of to blockade when given parenterally) administered as intermittent intravenous boluses of over , followed by to every (maximum ), or a continuous infusion of to . It decreases blood pressure without causing reflex tachycardia, making it a primary choice in acute aortic dissection, ischemic stroke, and preeclampsia/eclampsia, but is contraindicated in reactive airway disease, severe sinus bradycardia, high-degree heart block, and decompensated heart failure.
Esmolol: An ultrashort-acting, cardioselective -adrenergic antagonist with an elimination half-life of , administered as an intravenous loading dose of 500\,\text{\mu g/kg} over followed by a continuous infusion of 50\,\text{\mu g/kg/min}, titrated up to to 300\,\text{\mu g/kg/min}. It is preferred for acute aortic dissection when rapid titratability is required.
Fenoldopam: A selective dopamine receptor partial agonist that induces systemic and renal arteriolar vasodilation while promoting natriuresis, dosed at to 0.3\,\text{\mu g/kg/min} and titrated up to 1.6\,\text{\mu g/kg/min}. It maintains renal perfusion in acute renal insufficiency, but is contraindicated in glaucoma due to increased intraocular pressure.
Phentolamine: A competitive nonselective - and -adrenergic antagonist dosed at to intravenous bolus, indicated for hyperadrenergic crises (pheochromocytoma resection, monoamine oxidase inhibitor-tyramine reactions, cocaine toxicity, clonidine withdrawal). Unopposed -blockade must be avoided in these settings.
Hydralazine: An intravenous direct arteriolar vasodilator ( to every to ) with an unpredictable onset ( to ) and prolonged duration ( to ), limiting its utility as a first-line agent except in preeclampsia.
Enalaprilat: An intravenous inhibitor ( to over every , up to ), whose blood pressure response depends on circulating renin levels, making it unpredictable in acute crisis; it is contraindicated in acute myocardial infarction, pregnancy, and bilateral renal artery stenosis.
Hypertensive urgency is defined as severe blood pressure elevation () in a stable patient without acute or progressing target-organ damage. Hypertensive urgency does not warrant emergency department referral, acute parenteral medication, or hospital admission. Blood pressure should be lowered gradually over to using oral regimens: re-initiating or increasing doses of home medications, or adding a complementary oral agent (such as a thiazide diuretic or calcium channel blocker). Immediate blood pressure lowering in hypertensive urgency provides no proven clinical benefit and can precipitate ischemic vascular events; clinical outpatient re-evaluation is recommended within to .
Dyslipidemia: Primary and Secondary Prevention
Therapeutic management of dyslipidemia centers on reducing atherosclerotic cardiovascular disease () risk through lifestyle intervention, risk stratification, and evidence-based lipid-lowering pharmacotherapies. The 2018 cholesterol guidelines and the 2022 Expert Consensus Decision Pathway establish four primary patient management groups:
Clinical (Secondary Prevention): Individuals with acute coronary syndrome within the past , prior myocardial infarction, stable or unstable angina, coronary revascularization, stroke, transient ischemic attack, or peripheral arterial disease of atherosclerotic origin.
Severe Hypercholesterolemia: Adults aged to with baseline low-density lipoprotein cholesterol () of or greater.
Diabetes Mellitus: Adults aged to with diabetes and between and .
Primary Prevention: Adults aged to without diabetes or clinical , with between and , stratified by estimated 10-year risk calculated using the Pooled Cohort Equations ().
Primary prevention risk stratification via the assesses sex, age, race, total cholesterol, high-density lipoprotein cholesterol (), systolic blood pressure, current treatment for hypertension, diabetes status, and smoking status, defining four categories: Low Risk ( 10-year risk; managed with lifestyle alone); Borderline Risk ( to ; lifestyle modifications, with moderate-intensity statins considered if risk-enhancing factors are present); Intermediate Risk ( to ; moderate-intensity statin targeting an reduction of to ); and High Risk (; high-intensity statin targeting an reduction of ). Risk-enhancing factors include: family history of premature (first-degree male relative aged or female relative aged ); primary hypercholesterolemia ( to ); metabolic syndrome; chronic kidney disease ( to ); chronic inflammatory conditions (psoriasis, rheumatoid arthritis, lupus, HIV/AIDS); history of premature menopause (age ) or preeclampsia; high-risk ethnicity (e.g., South Asian ancestry); persistent hypertriglyceridemia (); and elevated circulating biomarkers (high-sensitivity C-reactive protein [] , lipoprotein(a) , or apolipoprotein B ). In intermediate-risk or select borderline-risk patients where the statin decision remains uncertain, measuring the coronary artery calcium () score provides risk refinement: a score of allows re-evaluation in without a statin (unless diabetes, active smoking, or family history of premature is present); a score of to favors statin initiation, particularly in individuals aged or older; and a score of or greater, or at/above the 75th percentile for age and sex, establishes a clear indication for statin initiation.
Statins (HMG-CoA reductase inhibitors) competitively inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis. Intracellular cholesterol depletion up-regulates cell-surface LDL receptor expression, promoting the clearance of circulating atherogenic apoB-containing lipoproteins. Statins reduce by to , decrease triglycerides by to , raise by to , and stabilize coronary atheroma. High-intensity statins lower by or greater: atorvastatin to daily and rosuvastatin to daily. Moderate-intensity statins reduce by to : atorvastatin to , rosuvastatin to , simvastatin to , pravastatin to , lovastatin to , fluvastatin twice daily or extended-release daily, and pitavastatin to daily. Low-intensity statins reduce by less than : simvastatin , pravastatin to , and lovastatin daily.
Statin pharmacokinetics differ in lipophilicity, clearance pathways, and drug-interaction profiles. Atorvastatin, lovastatin, and simvastatin are lipophilic molecules cleared primarily by CYP3A4, predisposing them to significant drug interactions with potent CYP3A4 inhibitors (azole antifungals, clarithromycin, erythromycin, protease inhibitors, cobicistat, dronedarone, and grapefruit juice exceeding ); simvastatin is restricted to with amiodarone, amlodipine, or ranolazine, and with diltiazem, verapamil, or dronedarone. Fluvastatin, pitavastatin, and rosuvastatin are metabolized via CYP2C9; rosuvastatin is hydrophilic, exhibits an elimination half-life of , and must not exceed in severe renal impairment () or with cyclosporine. Pravastatin is hydrophilic, cleared via sulfation without major cytochrome P450 involvement, and carries low drug-interaction risk. Co-administration of gemfibrozil with any statin (particularly simvastatin) is contraindicated due to inhibition of statin glucuronidation, which increases plasma exposure and risk of severe rhabdomyolysis; fenofibrate is preferred when combining fibrates with statins. In 2021, the FDA requested the removal of the absolute contraindication against statin use during pregnancy, though statins should still be discontinued in most pregnant and breastfeeding individuals.
Ezetimibe selectively inhibits the Niemann-Pick C1-Like 1 () transporter in the brush border of the jejunal enterocyte, blocking dietary and biliary cholesterol absorption to provide an incremental to reduction in . In the IMPROVE-IT trial, adding ezetimibe to simvastatin in post-ACS patients demonstrated a significant reduction in cardiovascular events, establishing ezetimibe as the preferred initial nonstatin adjuvant (Class I in very high-risk clinical with ; Class IIa in severe hypercholesterolemia with on maximally tolerated statins).
PCSK9 monoclonal antibodies (evolocumab and alirocumab) bind circulating proprotein convertase subtilisin/kexin type 9, preventing the targeted lysosomal degradation of hepatic LDL receptors and accelerating clearance. When added to statins, they produce an incremental to reduction in and reduce cardiovascular death, myocardial infarction, and stroke (FOURIER, ODYSSEY OUTCOMES). Evolocumab is dosed subcutaneously at every or once monthly; alirocumab is dosed subcutaneously at to every or every . Inclisiran is a small interfering RNA () conjugated to triantennary N-acetylgalactosamine () that targets hepatocyte asialoglycoprotein receptors to degrade intracellular PCSK9 messenger RNA, lowering by approximately . Inclisiran is administered subcutaneously as a injection at months 0 and 3, and every thereafter. Cardiovascular outcomes trials for inclisiran are ongoing.
Bempedoic acid inhibits adenosine triphosphate-citrate lyase (), an upstream enzyme in the hepatic cholesterol synthesis cascade preceding HMG-CoA reductase. Because the activating enzyme (very long-chain acyl-CoA synthetase 1) is present in the liver but absent in skeletal muscle, bempedoic acid lowers by to without causing muscle toxicity. In the CLEAR Outcomes trial of statin-intolerant patients, bempedoic acid significantly reduced . Bempedoic acid inhibits renal tubular organic anion transporter 2 (), leading to hyperuricemia ( to ) and an increased incidence of acute gout; it is also associated with a modest increase in tendon rupture, leukopenia, and elevated transaminases. Co-administration increases concentrations of simvastatin (limit to ) and pravastatin (limit to ).
Hypertriglyceridemia is categorized as moderate ( to ) or severe (, particularly ). Severe hypertriglyceridemia warrants immediate dietary fat restriction and pharmacotherapy to prevent acute pancreatitis. Secondary causes of hypertriglyceridemia must be evaluated: medications (anabolic steroids, atypical antipsychotics, -blockers, bile acid sequestrants, oral estrogens, glucocorticoids, protease inhibitors, raloxifene, oral retinoids, sirolimus, thiazide diuretics); dietary factors (excessive alcohol consumption, high-glycemic-index refined carbohydrates, extreme low-fat/high-carbohydrate diets, weight gain); and systemic diseases (uncontrolled diabetes, hypothyroidism, nephrotic syndrome, chronic kidney disease, lipodystrophies). In moderate hypertriglyceridemia, statin therapy is optimized to address cardiovascular risk; if triglycerides remain between and in patients with established or diabetes with two or more additional risk factors, prescription icosapent ethyl ( twice daily with meals) reduces by (REDUCE-IT). In severe hypertriglyceridemia (), fibrates (fenofibrate to daily, or fenofibric acid) represent first-line therapy to lower triglycerides by to via peroxisome proliferator-activated receptor-alpha () activation; gemfibrozil must not be combined with statins.
Clinical Case Studies and Practice Scenarios
Scenario 1: Optimizing GDMT in HFrEF with Active Volume Congestion
A 48-year-old woman (, body weight ) with alcohol-induced cardiomyopathy presents for follow-up. Her most recent echocardiogram reveals an of , and her functional status is consistent with Class III heart failure. Her current home medications include lisinopril daily, furosemide twice daily, carvedilol twice daily, spironolactone daily, and digoxin daily, which have remained unchanged for the past month. Vital signs include blood pressure and heart rate . Laboratory values demonstrate sodium , potassium , chloride , bicarbonate , blood urea nitrogen , serum creatinine , blood glucose , calcium , phosphorus , magnesium , and a serum digoxin concentration of . She reports worsening shortness of breath and progressive fatigue over the prior week. Physical examination reveals bilateral lower extremity pitting edema and inspiratory pulmonary crackles.
The most appropriate strategy to maximize the management of her heart failure is to add empagliflozin orally daily. SGLT2 inhibitors provide reductions in cardiovascular mortality and heart failure hospitalizations in symptomatic irrespective of diabetes status. Increasing carvedilol to twice daily is contraindicated during active fluid overload, as initiating or escalating -blockers in decompensated, hypervolemic patients precipitates acute clinical worsening; -blocker uptitration should be deferred until complete euvolemia is restored. Lisinopril is already at its maximum recommended heart failure dose (), and exceeding this threshold offers no incremental clinical benefit while increasing nephrotoxicity and hyperkalemia. Digoxin is at a therapeutic concentration (, within the target range of to ); increasing the dose to would raise serum concentrations above , conferring an increased risk of proarrhythmia and all-cause mortality without improving efficacy.
Scenario 2: Medication Optimization in Stable Stage C HFrEF with CKD
A 62-year-old man (, height , weight ) with a medical history of chronic coronary disease (myocardial infarction 3 years ago), hypertension, major depressive disorder, Stage 3 chronic kidney disease (baseline serum creatinine ), peripheral arterial disease, osteoarthritis, and hypothyroidism presents for routine evaluation of stable Class II heart failure ( ). Current medications include aspirin daily, atorvastatin every night, enalapril twice daily, metoprolol succinate daily, furosemide twice daily, cilostazol twice daily, acetaminophen four times daily, sertraline daily, and levothyroxine daily. Vital signs are blood pressure and heart rate . Laboratory values demonstrate potassium , serum creatinine , and thyroid-stimulating hormone () .
The optimal next step to improve his heart failure outcomes is to transition from enalapril to sacubitril/valsartan orally twice daily. Guidelines recommend replacing an inhibitor or with an in chronic symptomatic to decrease morbidity and mortality. A mandatory washout period between the last dose of enalapril and the first dose of sacubitril/valsartan must be observed. The lower starting dose ( twice daily) is indicated because the patient was taking a low dose of enalapril ( twice daily) and has severe chronic kidney disease. Substituting carvedilol for metoprolol succinate is not indicated, as both are evidence-based -blockers with equivalent efficacy in clinical trials. Adding spironolactone is contraindicated because his baseline serum creatinine () exceeds the safe threshold ( in men, or ), placing him at risk for life-threatening hyperkalemia. Adding digoxin is inappropriate because the patient is clinically stable, and his impaired renal function ( ) would lead to digitalis accumulation and toxicity.
Scenario 3: Identification of Harmful Medications in Systolic Heart Failure
Regarding the medications taken by the patient in Scenario 2 (), cilostazol should be discontinued immediately. Cilostazol is a phosphodiesterase type 3 inhibitor indicated for intermittent claudication in peripheral arterial disease; however, all phosphodiesterase type 3 inhibitors carry a boxed warning contraindicating their use in patients with heart failure of any severity due to increased ventricular arrhythmias and mortality. Acetaminophen is the analgesic of choice for mild to moderate musculoskeletal pain in heart failure because it avoids the fluid retention, hypertension, and renal impairment associated with . Sertraline is safe and carries no contraindication in heart failure. Levothyroxine is therapeutic (supported by a normal of ); maintaining euthyroid status is essential because untreated hypothyroidism impairs cardiac contractility and masks symptoms, whereas hyperthyroidism exacerbates systolic dysfunction.
Scenario 4: Anticoagulation Decision-Making in New-Onset Atrial Fibrillation
A 52-year-old man (, height , weight ) with a history of hypertension and a transient ischemic attack 2 years ago presents with an intermittent "fluttering" chest sensation over several weeks. He takes metoprolol tartrate twice daily and aspirin daily. He resides 3 hours from his primary care clinic. Vital signs are blood pressure and heart rate . Laboratory values are normal. An electrocardiogram reveals an irregularly irregular rhythm devoid of P waves with a ventricular response of , confirming atrial fibrillation.
The most appropriate management strategy is to initiate oral anticoagulation with dabigatran orally twice daily. His ventricular rate is well controlled () on his current -blocker; adding another nodal blocking agent (digoxin or diltiazem) is unnecessary and increases the risk of high-grade atrioventricular block. Evaluating stroke risk yields a score of 3 (hypertension = 1 point; prior = 2 points), establishing a Class I indication for chronic oral anticoagulation. Direct-acting oral anticoagulants () are preferred over warfarin. Dabigatran twice daily is appropriate because he has intact renal function, demonstrated adherence to a twice-daily regimen, prescription insurance, and an inability to travel for frequent monitoring.
Scenario 5: Managing Recurrent Atrial Fibrillation in Decompensated HFrEF
A 67-year-old man () with a 4-year history of hypertension and atrial fibrillation presents following emergency evaluation for worsening exertional fatigue, palpitations, and lower extremity edema. His medications include ramipril twice daily, sotalol twice daily, digoxin daily, and warfarin daily. Physical examination reveals worsening lower extremity pitting edema and blood pressure , heart rate , and . Telemetry displays atrial fibrillation, and an echocardiogram demonstrates a newly reduced of to . The physician elects to maintain a rhythm control strategy.
The most appropriate treatment modification is to discontinue sotalol and initiate amiodarone, loading with twice daily and tapering toward a maintenance dose of daily. Sotalol is contraindicated in left ventricular systolic dysfunction () and heart failure due to its negative inotropic properties and risk of torsades de pointes. Dronedarone is contraindicated in symptomatic heart failure with recent decompensation due to doubled mortality. Amiodarone and dofetilide are the only two antiarrhythmic agents demonstrated to be safe for rhythm control in . When initiating amiodarone, drug interactions must be addressed: the maintenance dose of warfarin must be reduced by to with close monitoring, and the digoxin dose must be reduced by .
Scenario 6: Antihypertensive Regimen Design in Post-MI Hypertension
A 55-year-old woman () recently hospitalized for an acute myocardial infarction treated with a drug-eluting coronary stent presents for follow-up. Her past medical history includes hypertension and gastroesophageal reflux disease. Current medications are clopidogrel daily, aspirin daily, and atorvastatin daily. Vital signs are blood pressure and heart rate . Laboratory values are within normal limits (sodium , potassium , serum creatinine ).
The most appropriate regimen to treat her hypertension is to initiate dual therapy with lisinopril and metoprolol succinate. Her blood pressure () represents Stage 2 hypertension (), exceeding her target () by more than , which warrants prompt initiation of two first-line agents of different classes. In patients with ischemic heart disease and prior myocardial infarction, guidelines specifically recommend combining an evidence-based -blocker with an inhibitor (or ) to attenuate neurohormonal activation, reduce myocardial oxygen demand, promote coronary remodeling, and lower recurrent ischemic events and mortality.
Scenario 7: First-Line Antihypertensive Selection in a Black Patient with Elevated ASCVD Risk
A 58-year-old African American woman () presents for follow-up of chronic obstructive pulmonary disease. Her blood pressure across two standardized visits averages , with a heart rate of . Current medications include daily tiotropium dry powder inhaler and an albuterol inhaler as needed. Laboratory values are normal ( , potassium ). Her calculated 10-year risk is .
The most appropriate management is to initiate lifestyle modifications and add amlodipine once daily. Her average blood pressure () represents Stage 1 hypertension. Because her 10-year risk is or greater, the pharmacotherapy threshold is , and lifestyle modifications alone are insufficient. Single-agent pharmacotherapy is indicated because her blood pressure is not above target. In Black adults without heart failure or chronic kidney disease with albuminuria, initial antihypertensive therapy should comprise a dihydropyridine calcium channel blocker (amlodipine) or a thiazide-like diuretic, as these classes achieve greater blood pressure reductions and cerebrovascular event reductions compared to inhibitors or .
Scenario 8: Statin Selection in Diabetes Mellitus with Multiple ASCVD Risk Factors
A 63-year-old woman () presents after 6 months of dietary and exercise modifications for dyslipidemia. Her medical history includes hypertension, type 2 diabetes mellitus, and asthma. She smokes one pack of cigarettes per day and consumes three beers daily. Her family history is significant for maternal myocardial infarction at age . Her medications are an albuterol inhaler, lisinopril, metformin, linagliptin, and calcium carbonate. Vital signs include blood pressure and heart rate . Fasting lipid panel reveals , , triglycerides , and total cholesterol ; hemoglobin is . Her estimated 10-year risk is .
The next step in therapy is to initiate a high-intensity statin (atorvastatin to or rosuvastatin to daily). In patients aged to with diabetes mellitus, moderate-intensity statin therapy is the baseline recommendation; however, when multiple high-risk factors are present (active cigarette smoking, hypertension, low , family history of premature , 10-year risk ), high-intensity statin therapy targeting an reduction of or greater is indicated. Initial combination therapy with ezetimibe is not recommended prior to assessing the response to maximally tolerated high-intensity statin monotherapy at a to follow-up.
Scenario 9: High-Intensity Statin Dosing Verification
According to cholesterol guidelines, high-intensity statin therapy is defined as a daily dose that lowers baseline by or greater. Atorvastatin daily meets this definition (producing an average reduction of approximately to ). Pravastatin and lovastatin are low-intensity regimens (lowering by ), whereas rosuvastatin daily is classified as moderate-intensity therapy ( to reduction).
Scenario 10: Differentiating Secondary Etiologies of Hypertriglyceridemia
When evaluating a patient with severe dyslipidemia, secondary causes of elevated triglycerides include immunosuppressive agents such as sirolimus. Sirolimus inhibits mammalian target of rapamycin (), impairing lipoprotein lipase activity and up-regulating hepatic very-low-density lipoprotein production, frequently causing severe hypertriglyceridemia. Other pharmacologic causes include anabolic steroids, atypical antipsychotics, -blockers, bile acid sequestrants, systemic glucocorticoids, oral estrogens, and protease inhibitors. Saturated dietary fats, amiodarone, and extrahepatic biliary obstruction predominantly increase , not triglycerides.
Scenario 11: Duration of Dual Antiplatelet Therapy Following DES for ACS
A 66-year-old man presents 14 months following an acute coronary syndrome treated with a drug-eluting coronary stent. His medications include aspirin , prasugrel , sublingual nitroglycerin as needed, metoprolol succinate , ramipril , and atorvastatin . He inquires about the required duration of prasugrel therapy.
The most appropriate instruction is to advise him to consult his physician regarding discontinuing prasugrel at this time. Standard guidelines recommend a minimum duration of of following for . Beyond , continued is warranted only in select patients with high ischemic risk and low bleeding vulnerability. Because this patient has achieved of uneventful therapy without ongoing ischemic symptoms, transitioning to single antiplatelet therapy with lifelong aspirin daily is the standard course.
Scenario 12: Pharmacologic Conversion and Antiarrhythmic Safety in Post-MI Sustained VT
A 68-year-old man with a history of Class III heart failure ( ), two previous myocardial infarctions, long-standing hypertension, and diabetic nephropathy ( ) is admitted following a syncopal episode. Telemetry documents a episode of sustained monomorphic ventricular tachycardia. Vital signs are blood pressure and heart rate .
The most appropriate intravenous antiarrhythmic regimen for acute conversion is amiodarone infused over , followed by for , then for . Class I antiarrhythmics, including procainamide, are contraindicated in patients with an and ischemic cardiomyopathy due to proarrhythmia and negative inotropy. Sotalol is contraindicated in patients with an and carries a risk of torsades de pointes in renal insufficiency ( ). Dofetilide is ineffective for acute ventricular tachycardia conversion and is indicated only for atrial fibrillation or flutter. Amiodarone is safe and effective for sustained ventricular tachycardia in the setting of severe left ventricular systolic dysfunction and chronic kidney disease.
Scenario 13: Duration of Extracardiac Toxicity Following Amiodarone Discontinuation
If the patient in Scenario 12 subsequently develops amiodarone-induced thyrotoxicosis leading to recurrent ventricular tachycardia, requiring amiodarone cessation, the anticipated duration of hyperthyroidism is approximately 6 months. Amiodarone has an elimination half-life averaging to due to extensive sequestration in adipose and parenchymal tissues. Resolving systemic toxicities requires three to five elimination half-lives (approximately to ) following complete drug cessation.
Scenario 14: Management of QTc Prolongation Induced by Sotalol
A 64-year-old woman with a history of hypertension and an inferior myocardial infarction 6 months ago develops sustained ventricular tachycardia successfully converted with intravenous lidocaine. Electrophysiologic testing confirms inducible ventricular tachycardia, and she is started on sotalol orally twice daily. Two hours following the second dose, an electrocardiogram reveals a interval of .
The most appropriate management is to discontinue sotalol and initiate oral amiodarone ( three times daily loading). A exceeding during sotalol therapy confers an unacceptably high risk of drug-induced torsades de pointes, mandating immediate discontinuation. Dofetilide is also a Class III potassium channel blocker with reverse use-dependence and would carry a comparable risk of excessive prolongation; furthermore, it is not approved for ventricular arrhythmias. Amiodarone prolongs the action potential duration uniformly with minimal dispersion of ventricular repolarization, conferring a low risk of torsades de pointes () and serving as a safe alternative in structural heart disease.
Scenario 15: Treatment Selection in Acute Hypertensive Emergency with Pulmonary Edema
A 68-year-old man with end-stage renal disease on maintenance hemodialysis, chronic coronary disease, , and recent cocaine use presents with acute dyspnea, diaphoresis, severe chest tightness, blood pressure , heart rate , bilateral pulmonary crackles, and ST-segment depression in inferior leads. He has missed dialysis and gained .
The most appropriate intervention is continuous intravenous nitroglycerin (5\,\text{\mu g/min}, titrated to achieve a maximum reduction in over the first hour). The patient is presenting with a hypertensive emergency complicated by acute pulmonary edema and acute myocardial ischemia. Nitroglycerin provides rapid venodilation to decrease preload, lower pulmonary capillary wedge pressure, relieve pulmonary congestion, and dilate epicardial coronary arteries without compromising renal clearance. Sodium nitroprusside is contraindicated due to anuria, which prevents the renal clearance of thiocyanate, resulting in rapid thiocyanate toxicity. Labetalol and other -blockers are contraindicated in acute decompensated heart failure with pulmonary edema; furthermore, lowering by is overly precipitous and risks cerebral and coronary hypoperfusion. Oral clonidine cannot be titrated predictably in hypertensive emergencies and provides no role in acute pulmonary edema.
Scenario 16: Hypertensive Urgency Secondary to Medication Nonadherence
A 56-year-old woman with chronic hypertension and nonischemic heart failure ( ) presents to the emergency department with a blood pressure of and a heart rate of . She reports running out of her chronic medications (hydrochlorothiazide, carvedilol, and lisinopril) 3 days ago. She feels mildly lightheaded but exhibits no chest pain, shortness of breath, visual changes, or focal neurologic deficits. Laboratory evaluations and electrocardiography are normal.
The most appropriate strategy is to resume her home oral antihypertensive regimen and arrange outpatient clinical follow-up within . In hypertensive urgency (severe blood pressure elevation in the absence of acute target-organ damage), intravenous antihypertensives and emergency hospitalization are not indicated and are associated with adverse outcomes. The patient's elevation is secondary to abrupt cessation of maintenance therapies; restarting her outpatient regimen restores blood pressure control safely over to . Adding an immediate fourth agent is unnecessary until adherence to her baseline three-drug regimen has been re-established.